Many of our doctors are constantly vigilant about our developing skeletal related issues. Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of [...]
Most people don't know the many advances that the Department of Defense Congressionally Directed Medical Research Program (DOD PCRP) has brought to the PROSTATE CANCER COMMUNITY. Did you know that the program is directly responsible for funding the initial development of three of the very new drugs we have available? The DOD PCRP is directly [...]
At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor (AR) splice variants in men with advanced prostate cancer. Their work relies on the premise that AR-V7 expression underlies resistance [...]
We have many new drugs to treat metastatic castrate resistant prostate cancer (mCRPC), but not all men have a positive result to each of the drug. Understanding who might obtain a positive result to a specific drug prior giving it will save both the individual man and society time and money. Understanding this it becomes [...]
There is more evidence that the blood test used to count the number of cells circulating in the blood and shed from prostate tumors (circulating tumor cells or CTCs) can indicate whether a treatment is working or not working. A major new study showed that the number of these circulating tumor cells in the blood [...]